{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T05:57:23Z","timestamp":1733983043008,"version":"3.30.2"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ctro.2024.100896","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:10:53Z","timestamp":1732637453000},"page":"100896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy"],"prefix":"10.1016","volume":"50","author":[{"given":"Benjamin","family":"Challis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kneebone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Eade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Atyeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100896_b0005","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer\u2013specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2024.100896_b0010","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2024.100896_b0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00066-018-1417-9","article-title":"Comparison of 68 Ga-PSMA ligand PET\/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer","volume":"195","author":"Walacides","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctro.2024.100896_b0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer\u2013specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2024.100896_b0025","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1002\/cncr.25993","article-title":"Salvage radiation in men after prostate-specific antigen failure and the risk of death","volume":"117","author":"Cotter","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2024.100896_b0030","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin Adv Hematol Oncol H&O"},{"key":"10.1016\/j.ctro.2024.100896_b0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1754-9485.12139","article-title":"FROGG high-risk prostate cancer workshop: patterns of practice and literature review. Part II post-radical prostatectomy","volume":"58","author":"Lehman","year":"2014","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100896_b0040","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2015.04.103","article-title":"Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature","volume":"194","author":"Ploussard","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2024.100896_b0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100896_b0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.radonc.2008.05.006","article-title":"Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand radiation oncology Genito-urinary group","volume":"88","author":"Sidhom","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100896_b0055","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2024.100896_b0060","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100896_b0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2024.100896_b0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2024.100896_b0075","article-title":"Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: the POPART multicentric prospective study","volume":"44","author":"Ferrario","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100896_b0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.euf.2020.12.010","article-title":"The multicenter, randomized, phase 2 PEACE V-STORM trial: defining the best salvage treatment for oligorecurrent nodal prostate cancer metastases","volume":"7","author":"Zilli","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctro.2024.100896_b0085","doi-asserted-by":"crossref","first-page":"S2485","DOI":"10.1016\/S0167-8140(24)02299-0","article-title":"2007: Salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM)","volume":"194","author":"Ost","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100896_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-019-1383-0","article-title":"Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice","volume":"14","author":"Panje","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100896_b0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100896_b0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijrobp.2015.03.021","article-title":"Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy","volume":"92","author":"Harris","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100896_b0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100896_b0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-023-02302-8","article-title":"Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer","volume":"18","author":"Mohan","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100896_b0115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00066-020-01605-z","article-title":"PSMA-positive nodal recurrence in prostate cancer: salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis","volume":"196","author":"Schmidt-Hegemann","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctro.2024.100896_b0120","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.juro.2017.12.048","article-title":"Contemporary incidence and outcomes of prostate cancer lymph node metastases","volume":"199","author":"Bernstein","year":"2018","journal-title":"J Urol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:31:09Z","timestamp":1733959869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824001733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"alternative-id":["S2405630824001733"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100896","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100896"}}